<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173390</url>
  </required_header>
  <id_info>
    <org_study_id>SDC DT 023/19/122</org_study_id>
    <secondary_id>17907319.5.0000.8069</secondary_id>
    <nct_id>NCT04173390</nct_id>
  </id_info>
  <brief_title>PREemptive Analgesia With preGABAlin in HEART Surgery</brief_title>
  <acronym>PREGABA-HEART</acronym>
  <official_title>Preemptive Analgesia With Pregabalin in Heart Surgery: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Postoperative pain after cardiac surgery has high incidence and is associated
      with worse morbidity. Pregabalin is a new antiepileptic drug used in patients with chronic
      pain and has been studied even more in postoperative. OBJECTIVE: Evaluate whether preemptive
      pregabalin use compared with placebo decreases pain perception in patients undergoing cardiac
      surgery in the first 24 hours and 2 months after hospital discharge; evaluate analgesic
      consumption in the immediate postoperative period; evaluate differences in blood gas
      parameters between groups; evaluate anesthetic recovery by QoR-40; assess incidence of
      serious adverse events (reintubation and mental confusion); incidence of delirium through the
      CAM-ICU questionnaire; assess adverse drug events (nausea, vomiting, pharmacodermia, allergic
      reactions). METHOD: Randomized, triple-blind, placebo-controlled clinical trial. EXPECTED
      RESULTS: Postoperative pain control with a drug that could cause fewer side effects, may lead
      to faster clinical improvement, fewer medications and fewer procedures, and lower healthcare
      costs with a decrease in intensive care unit (ICU) stay.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain perception in visual analog scale (0 means no pain and 10 is the severe pain) at 24 hour post operative</measure>
    <time_frame>24 hours post operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pain perception in visual analog scale (0 means no pain and 10 is the severe pain) at month 2 post operative</measure>
    <time_frame>Month 2 post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in analgesic consumption</measure>
    <time_frame>24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of oxygen in millimeter of mercury (mmHg)</measure>
    <time_frame>24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of carbon dioxide in millimeter of mercury (mmHg)</measure>
    <time_frame>24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood potential of hydrogen (pH)</measure>
    <time_frame>24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation in percentage (%)</measure>
    <time_frame>24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic recovery by Quality of Recovery 40-item questionnaire (QoR-40 - 40 items questionnaire each item ranging from 1 to 5 being 1 very poor and 5 excellent)</measure>
    <time_frame>24 hour post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (reintubation and mental confusion)</measure>
    <time_frame>24 hour post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium by Confusion Assessed Method fo the Intensive Care Unity (CAM-ICU)</measure>
    <time_frame>24 hour post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse drug events (nausea, vomiting, pharmacodermia, allergic reactions) assessed by Common Terminology Criteria for Adverse Events (CTCAE v5.0)</measure>
    <time_frame>24 hour post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day</description>
    <arm_group_label>pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will undergo median sternotomy due to the need for cardiac surgery
             (valvular or myocardial revascularization);

          -  Patients between 18 and 70 years old;

          -  Patients able to swallow tablets and agree to participate in this clinical trial.

        Exclusion Criteria:

          -  Patients with chronic renal failure with creatinine clearance less than or equal to 30
             mL/min;

          -  Patients with known hypersensitivity to pregabalin;

          -  Hemodynamically unstable patients using vasoactive drugs the day before surgery;

          -  Unconscious and/or sedated patients, or without cognitive discernment to use the
             visual analog scale;

          -  Patients previously submitted to sternotomy; emergency surgery;

          -  Patients with neurological diseases; anticonvulsant drug users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Antonio M Cesar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno R Barbosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André T Araújo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFPB Paraíba Federal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno R Barbosa, MD</last_name>
    <phone>+5583991825520</phone>
    <email>robalinho@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital João XXIII</name>
      <address>
        <city>Campina Grande</city>
        <state>Paraíba</state>
        <zip>58400-515</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno R Barbosa, MD</last_name>
      <phone>+5583991825520</phone>
      <email>robalinho@usp.br</email>
    </contact>
    <investigator>
      <last_name>André T Araújo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno R Barbosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Dom Rodrigo</name>
      <address>
        <city>João Pessoa</city>
        <state>Paraíba</state>
        <zip>58013-470</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Andre T Araújo, PhD</last_name>
      <phone>+5583993091303</phone>
      <email>andre_telis@globo.com</email>
    </contact>
    <investigator>
      <last_name>André T Araújo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Bruno Robalinho Cavalcanti Barbosa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

